ASCO: Targeted therapy induces responses in HER2-amplified biliary tract cancer
HER2-targeted bispecific antibody zanidatamab demonstrated durable responses in patients with treatment-refractory HER2-positive biliary tract cancer (BTC), researchers from The University of Texas MD Anderson Cancer Center ...
Jun 3, 2023
0
6